Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America” Journal of Cardiac Failure Vol. 25 No. 8, pp. 584-619

Abstract

In the above article a correction is needed. On page 601, left hand column, in the “Use of Glucose-Lowering Medications With CKD” section, first paragraph, the last sentence read, “Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CANVAS [just stopped prematurely for efficacy]…” It should have read,” Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min−1·1.73 m−2, ongoing trials (CREDENCE [just stopped prematurely for efficacy]…” Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of AmericaJournal of Cardiac FailureVol. 25Issue 8PreviewType 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. Full-Text PDF